A systematic review and meta-analysis of the role of ABCC2 variants on drug response in patients with epilepsy

Epilepsia

Volumn 54, Issue 5, 2013, Pages 936-945

  Grover, Sandeep ^a   Kukreti, Ritushree ^a  

^a CSIR INSTITUTE OF GENOMICS AND INTEGRATIVE BIOLOGY   (India)

Author keywords

Antiepileptic drugs; Drug response; Phar macogenomics

Indexed keywords

ANTICONVULSIVE AGENT;

ABCC2 GENE; ARTICLE; DRUG RESPONSE; EPILEPSY; GENE; GENE FREQUENCY; GENETIC HETEROGENEITY; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; META ANALYSIS (TOPIC); PHENOTYPE; PRIORITY JOURNAL; PUBLISHING; SEIZURE; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW;

EID: 84876928269     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/epi.12132     Document Type: Article

References (44)

1. Aronica E, Gorter JA, Ramkema M, Redeker S, Ozbas-Gerceker F, van Vliet EA, Scheffer GL, Scheper RJ, van der Valk P, Baayen JC, Troost D,. (2004) Expression and cellular distribution of multidrug resistance-related proteins in the hippocampus of patients with mesial temporal lobe epilepsy. Epilepsia 45: 441-451.
2. Aronica E, Gorter JA, Redeker S, van Vliet EA, Ramkema M, Scheffer GL, Scheper RJ, van der Valk P, Leenstra S, Baayen JC, Spliet WG, Troost D,. (2005) Localization of breast cancer resistance protein (BCRP) in microvessel endothelium of human control and epileptic brain. Epilepsia 46: 849-857.
3. Baltes S, Fedrowitz M, Tortos CL, Potschka H, Loscher W,. (2007) Valproic acid is not a substrate for P-glycoprotein or multidrug resistance proteins 1 and 2 in a number of in vitro and in vivo transport assays. J Pharmacol Exp Ther 320: 331-343.
4. Begg CB, Mazumdar M,. (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50: 1088-1101.
5. Birbeck GL,. (2012) Revising and refining the epilepsy classification system: priorities from a developing world perspective. Epilepsia 53 (Suppl. 2): 18-21.
6. Bournissen FG, Moretti ME, Juurlink DN, Koren G, Walker M, Finkelstein Y,. (2009) Polymorphism of the MDR1/ABCB1 C3435T drug-transporter and resistance to anticonvulsant drugs: a meta-analysis. Epilepsia 50: 898-903.
7. Cascorbi I,. (2011) P-glycoprotein: tissue distribution, substrates, and functional consequences of genetic variations. Handb Exp Pharmacol 201: 261-283.
8. Cavalleri GL, McCormack M, Alhusaini S, Chaila E, Delanty N,. (2011) Pharmacogenomics and epilepsy: the road ahead. Pharmacogenomics 12: 1429-1447.
9. Cochran WG,. (1954) The combination of estimates from different experiments. Biometrics 10: 101-129.
10. DerSimonian R, Laird N,. (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177-188.
11. Dombrowski SM, Desai SY, Marroni M, Cucullo L, Goodrich K, Bingaman W, Mayberg MR, Bengez L, Janigro D,. (2001) Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy. Epilepsia 42: 1501-1506.
12. Egger M, Davey Smith G, Schneider M, Minder C,. (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634.
13. Glauser TA,. (2011) Biomarkers for antiepileptic drug response. Biomark Med 5: 635-641.
14. Grover S, Gourie-Devi M, Baghel R, Sharma S, Bala K, Gupta M, Narayanasamy K, Varma B, Kaur K, Talwar P, Kaur H, Giddaluru S, Sharma A, Brahmachari SK, Indian Genome Variation C, Kukreti R,. (2010) Genetic profile of patients with epilepsy on first-line antiepileptic drugs and potential directions for personalized treatment. Pharmacogenomics 11: 927-941.
15. Grover S, Gupta M, Kukreti R,. (2011) Challenges and recommendations for conducting epidemiological studies in the field of epilepsy pharmacogenetics. Indian J Hum Genet 17 (Suppl. 1): S4-S11.
16. Grover S, Gourie-Devi M, Bala K, Sharma S, Kukreti R,. (2012) Genetic association analysis of transporters identifies ABCC2 loci for seizure control in women with epilepsy on first-line antiepileptic drugs. Pharmacogenet Genomics 22: 447-465.
17. Haerian BS, Lim KS, Tan CT, Raymond AA, Mohamed Z,. (2011) Association of ABCB1 gene polymorphisms and their haplotypes with response to antiepileptic drugs: a systematic review and meta-analysis. Pharmacogenomics 12: 713-725.
18. Hilger E, Reinthaler EM, Stogmann E, Hotzy C, Pataraia E, Baumgartner C, Zimprich A, Zimprich F,. (2012) Lack of association between ABCC2 gene variants and treatment response in epilepsy. Pharmacogenomics 13: 185-190.
19. Kasperaviciute D, Sisodiya SM,. (2009) Epilepsy pharmacogenetics. Pharmacogenomics 10: 817-836.
20. Kim DW, Lee SK, Chu K, Jang IJ, Yu KS, Cho JY, Kim SJ,. (2009) Lack of association between ABCB1, ABCG2, and ABCC2 genetic polymorphisms and multidrug resistance in partial epilepsy. Epilepsy Res 84: 86-90.
21. Kim WJ, Lee JH, Yi J, Cho YJ, Heo K, Lee SH, Kim SW, Kim MK, Kim KH, Lee BI, Lee MG,. (2010) A nonsynonymous variation in MRP2/ABCC2 is associated with neurological adverse drug reactions of carbamazepine in patients with epilepsy. Pharmacogenet Genomics 20: 249-256.
22. Kroetz DL,. (2006) Role for drug transporters beyond tumor resistance: hepatic functional imaging and genotyping of multidrug resistance transporters for the prediction of irinotecan toxicity. J Clin Oncol 24: 4225-4227.
23. Kubota H, Ishihara H, Langmann T, Schmitz G, Stieger B, Wieser HG, Yonekawa Y, Frei K,. (2006) Distribution and functional activity of P-glycoprotein and multidrug resistance-associated proteins in human brain microvascular endothelial cells in hippocampal sclerosis. Epilepsy Res 68: 213-228.
24. Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, Moshe SL, Perucca E, Wiebe S, French J,. (2010) Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 51: 1069-1077.
25. Kwan P, Wong V, Ng PW, Lui CH, Sin NC, Wong KS, Baum L,. (2011) Gene-wide tagging study of the association between ABCC2, ABCC5 and ABCG2 genetic polymorphisms and multidrug resistance in epilepsy. Pharmacogenomics 12: 319-325.
26. Laechelt S, Turrini E, Ruehmkorf A, Siegmund W, Cascorbi I, Haenisch S,. (2011) Impact of ABCC2 haplotypes on transcriptional and posttranscriptional gene regulation and function. Pharmacogenomics J 11: 25-34.
27. Lau J, Ioannidis JP, Schmid CH,. (1997) Quantitative synthesis in systematic reviews. Ann Intern Med 127: 820-826.
28. Lazarowski A, Lubieniecki F, Camarero S, Pomata H, Bartuluchi M, Sevlever G, Taratuto AL,. (2004) Multidrug resistance proteins in tuberous sclerosis and refractory epilepsy. Pediatr Neurol 30: 102-106.
29. Lewis S, Clarke M,. (2001) Forest plots: trying to see the wood and the trees. BMJ 322: 1479-1480.
30. Loscher W, Potschka H,. (2005) Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci 6: 591-602.
31. Luna-Tortos C, Fedrowitz M, Loscher W,. (2010) Evaluation of transport of common antiepileptic drugs by human multidrug resistance-associated proteins (MRP1, 2 and 5) that are overexpressed in pharmacoresistant epilepsy. Neuropharmacology 58: 1019-1032.
32. Mantel N, Haenszel W,. (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22: 719-748.
33. Nguyen TD, Markova S, Liu W, Gow JM, Baldwin RM, Habashian M, Relling MV, Ratain MJ, Kroetz DL,. (2012) Functional characterization of ABCC2 promoter polymorphisms and allele-specific expression. Phar-macogenomics J June 5 [Epub ahead of print]. doi: 10.1038/tpj.2012.20
34. Niemi M, Arnold KA, Backman JT, Pasanen MK, Godtel-Armbrust U, Wojnowski L, Zanger UM, Neuvonen PJ, Eichelbaum M, Kivisto KT, Lang T,. (2006) Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics. Pharmacogenet Genomics 16: 801-808.
35. Nurmohamed L, Garcia-Bournissen F, Buono RJ, Shannon MW, Finkelstein Y,. (2010) Predisposition to epilepsy-does the ABCB1 gene play a role? Epilepsia 51: 1882-1885.
36. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS,. (2001) Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 276: 36734-36741.
37. Potschka H,. (2012) Role of CNS efflux drug transporters in antiepileptic drug delivery: overcoming CNS efflux drug transport. Adv Drug Deliv Rev 64: 943-952.
38. Qu J, Zhou BT, Yin JY, Xu XJ, Zhao YC, Lei GH, Tang Q, Zhou HH, Liu ZQ,. (2012) ABCC2 polymorphisms and haplotype are associated with drug resistance in chinese epileptic patients. CNS Neurosci Ther 18: 647-651.
39. Radhakrishnan K,. (2009) Challenges in the management of epilepsy in resource-poor countries. Nat Rev Neurol 5: 323-330.
40. Seo T, Ishitsu T, Oniki K, Abe T, Shuto T, Nakagawa K,. (2008) ABCC2 haplotype is not associated with drug-resistant epilepsy. J Pharm Pharmacol 60: 631-635.
41. Ufer M, Mosyagin I, Muhle H, Jacobsen T, Haenisch S, Hasler R, Faltraco F, Remmler C, von Spiczak S, Kroemer HK, Runge U, Boor R, Stephani U, Cascorbi I,. (2009) Non-response to antiepileptic pharmacotherapy is associated with the ABCC2 -24C>T polymorphism in young and adult patients with epilepsy. Pharmacogenet Genomics 19: 353-362.
42. Tishler DM, Weinberg KI, Hinton DR, Barbaro N, Annett GM, Raffel C,. (1995) MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia 36: 1-6.
43. Ufer M, von Stulpnagel C, Muhle H, Haenisch S, Remmler C, Majed A, Plischke H, Stephani U, Kluger G, Cascorbi I,. (2011) Impact of ABCC2 genotype on antiepileptic drug response in Caucasian patients with childhood epilepsy. Pharmacogenet Genomics 21: 624-630.
44. Zintzaras E, Ioannidis JP,. (2005) Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol 28: 123-137.